[Form 4] Cardinal Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Effective June 30, 2025, the Statement of Additional Information (SAI) for John Hancock Financial Opportunities Fund (ticker BTO), John Hancock Investors Trust and John Hancock Premium Dividend Fund is updated to reflect two governance changes:

• Paul Lorentz has resigned as a non-independent Trustee of each fund.
• Kristie M. Feinberg, already serving as each fund’s President and CEO of John Hancock Investment Management, has been appointed as a non-independent Trustee effective the same date and will stand for shareholder election in 2026.

The SAI now lists Ms. Feinberg’s extensive leadership background, including her roles at Manulife Investment Management, Invesco and Oppenheimer Funds, underscoring her experience in finance, strategy and product distribution. The board-class assignment for the Financial Opportunities Fund and Premium Dividend Fund places her term expiring in 2026. The John Hancock Fund Complex comprises 186 funds as of April 30, 2025.

No portfolio, financial or strategic policy changes are disclosed; the supplement is solely a board-composition update, to be read in conjunction with the current SAI.

Insights

Corporate Governance Expert

TL;DR: Routine trustee rotation; governance impact minimal, investment thesis unchanged.

The filing records a normal board transition: Paul Lorentz exits, Kristie Feinberg joins as non-independent Trustee while retaining her President role. Her deep asset-management résumé adds relevant expertise, but because she is already the funds’ CEO, her new board seat merely formalizes influence she effectively possessed. No disclosure suggests strategic, fee, or policy adjustments. Closed-end fund investors should view the change as administrative; it neither alters distribution policy nor portfolio management. Oversight independence remains intact, as the majority of Trustees are still independent, so regulatory risk is low.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Snow Ola M

(Last) (First) (Middle)

7000 CARDINAL PLACE

(Street)

DUBLIN OH 43017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CARDINAL HEALTH INC [ CAH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/30/2025		F(1)		3,623	D	$167.18(2)	23,538	D
Common Shares								147	I	By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the deferred settlement of performance share units.

2. Reflects closing price on prior business day.

Remarks:

	/s/ James E. Barnett, Attorney-in-fact	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.